|
Garbsen, Germany, (February 5th 2024). ARRALYZE®, the Life Science arm of LPKF Laser & Electronics SE, proudly announces the commercial availability of the CellShepherd®. After a successful beta-testing phase in 2023, this groundbreaking platform is now ready to revolutionize cell-based research and development across biomedical and various life science fields.
CellShepherd®: Redefining Single-Cell Analysis CellShepherd®, developed by ARRALYZE®, responds to the urgent need for advanced functional cell screening technologies in academic and industrial laboratories. It stands out with ARRALYZE’s proprietary nanowell glass arrays, which miniaturize cell-based assays while enabling real-time monitoring at the single-cell level. This autonomous platform boasts precise dispensing into nanoliter glass wells and supports (co)-culturing under climate-controlled, sterile conditions. Its capabilities extend to real-time imaging through a brightfield microscope and three fluorescent channels. Leveraging advanced AI-driven analysis, CellShepherd® accurately counts and tracks cells, offering vital insights into various parameters. This innovation promises a new era in scientific research characterized by precision, control, and deep insights. Meeting Market Demands: The ARRALYZE® Vision CellShepherd® is designed to fulfill the growing demand for technologies capable of studying small and large cell populations at the single-cell level and isolating target cells. By adopting a holistic approach, ARRALYZE® enables customers to uncover individual characteristics of heterogeneous cell populations and gain insight into the kinetics of experiments, monitoring functionality at different time points. This approach overcomes challenges such as harsh experiment conditions, limited microenvironment control, and difficulties maintaining cell viability. Key Features and Benefits
About LPKF LPKF Laser & Electronics SE, the parent company of ARRALYZE, is a leading provider of laser-based solutions for the technology industry. Founded in 1976, the company is headquartered in Germany, and is active worldwide through subsidiaries and representatives. The establishment of ARRALYZE as a dedicated division signifies LPKF’s commitment to innovation and excellence in the biotechnological sector. LPKF Laser & Electronics SE shares are traded in the Prime Standard segment of Deutsche Börse (ISIN 0006450000). Contact For more information about CellShepherd® and ARRALYZE®, please visit www.arralyze.com or contact us by email at info@arralyze.com ARRALYZE is part of LPKF group: LPKF Laser & Electronics SE Osteriede 7 D-30827 Garbsen Fon: +49 (0) 5131 7095-0 Fax: +49 (0) 5131 7095-90 www.lpkf.com End of Media Release Issuer: LPKF Laser & Electronics SE Key word(s): Research/Technology
05.02.2024 CET/CEST Dissemination of a Press Release, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | LPKF Laser & Electronics SE |
| Osteriede 7 | |
| 30827 Garbsen | |
| Germany | |
| Phone: | +49 (0) 5131 7095-0 |
| Fax: | +49 (0) 5131 7095-95 |
| E-mail: | investorrelations@lpkf.com |
| Internet: | www.lpkf.com |
| ISIN: | DE0006450000 |
| WKN: | 645000 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1822061 |
| End of News | EQS Media |
|
|
1822061 05.02.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
